With cases of arrhythmia and heart disease on the rise—thanks in large part to an aging global population—more tools and technologies are needed to speed up the process of diagnosing and beginning treatment for these and other heart conditions.

随着心律失常和心脏病病例的增加，很大程度上要归功于全球人口老龄化，需要更多的工具和技术来加速诊断和开始治疗这些和其他心脏病的过程。

Coming right up: The FDA has cleared a new software platform that fully automates the process of interpreting electrocardiograms, helping triage potential cases of irregular heart rhythms. The software comes from New York City-based AccurKardia, which announced the regulatory news this week.

即将到来：FDA已经清理了一个新的软件平台，可以完全自动化解释心电图的过程，帮助分类潜在的不规则心律病例。该软件来自位于纽约市的Accurkardi，该公司本周公布了监管新闻。

The AccurECG system was cleared to analyze results for patients aged 22 and older.

AccurECG系统已被清除，以分析22岁及以上患者的结果。

AccurKardia’s software relies on artificial intelligence algorithms and other technologies to scan readouts collected by a variety of compatible ECG devices. It parses through the peaks and valleys of each readout, performing beat-by-beat analyses, measuring each patient’s heart rate and looking for specific indicators of cardiac conditions..

AccurKardia的软件依靠人工智能算法和其他技术来扫描各种兼容ECG设备收集的读数。它解析每个读数的峰谷，进行逐搏分析，测量每个患者的心率并寻找心脏状况的具体指标。。

The analysis takes only a few minutes, per AccurKardia. Once finished, the system churns out a report that highlights signs of a baker’s dozen abnormal heart rhythms—including atrial fibrillation, tachycardia, bradycardia and more.

每个AccurKardia只需要几分钟的时间。一旦完成，系统就会产生一份报告，突出显示面包商十几种异常心律的迹象，包括心房颤动，心动过速，心动过缓等。

In a retrospective study of the technology that AccurKardia included in its application to the FDA, researchers found that AccurECG was able to detect those 13 forms of arrhythmia with about 96% sensitivity and 99% specificity.

在对AccurKardia应用于FDA的技术的回顾性研究中，研究人员发现AccurECG能够以约96%的灵敏度和99%的特异性检测这13种形式的心律失常。

AccurKardia is hoping that its software—which is housed on the cloud and can slot into a hospital or clinic’s existing cardiac workflows—will bring “specialist-level ECG interpretation” within reach for doctors and patients across the U.S. who may not otherwise have access to that level of analysis, Chief Medical Officer Nav Razvi, M.D., said in the announcement..

AccurKardia希望其位于云中并可插入医院或诊所现有心脏工作流程的软件能够为美国各地的医生和患者提供“专家级心电图解释”，否则他们可能无法获得该级别的分析。首席医疗官Nav Razvi，M.D。在公告中说。。

“By providing a device-agnostic, medical-grade solution with explainable output and no ‘black box’ approach, we aim to empower healthcare providers with accurate, fast, efficient and transparent ECG interpretation,” CEO Juan Jiménez added.

首席执行官Juan Jiménez补充说：“通过提供具有可解释输出且无需“黑匣子”方法的设备不可知的医疗级解决方案，我们的目标是为医疗服务提供者提供准确，快速，高效和透明的心电图解释。

AccurKardia is far from alone in developing new tools to automatically spot signs of arrhythmia and other heart conditions. Medtech makers like Eko, iRhythm and more are infusing AI into clinical tools, patient monitoring devices and software platforms to catch the conditions as early and accurately as possible..

AccurKardia在开发新工具以自动发现心律失常和其他心脏病的迹象方面远非独自一人。像Eko，iRhythm等Medtech制造商正在将AI注入临床工具，患者监测设备和软件平台，以尽早准确地捕捉病情。。

And beyond the traditional realm of medtech, consumer tech giants like Apple, Fitbit and Samsung have all added afib detection features to their respective smartwatches, making arrhythmia diagnoses even more broadly accessible.

除了medtech的传统领域之外，苹果，Fitbit和三星等消费科技巨头都在各自的智能手表上增加了afib检测功能，使心律失常诊断更加广泛。